Merck
  • Home
  • Search Results
  • Polymorphisms of NRF2 and NRF2 target genes in urinary bladder cancer patients.

Polymorphisms of NRF2 and NRF2 target genes in urinary bladder cancer patients.

Journal of cancer research and clinical oncology (2014-06-13)
Edyta Reszka, Zbigniew Jablonowski, Edyta Wieczorek, Ewa Jablonska, Magdalena Beata Krol, Jolanta Gromadzinska, Adam Grzegorczyk, Marek Sosnowski, Wojciech Wasowicz
ABSTRACT

NRF2 transcription factor is involved in modulation of various antioxidant and metabolic genes and, therefore, may modulate anti-carcinogenic potential. Association between polymorphisms of NRF2 and five NRF2-regulated genes and urinary bladder cancer (BC) risk was analyzed. The study group included 244 BC patients, while the control group comprised 365 individuals with no evidence of malignancy. Genotyping of GSTM1 (deletion), GSTT1 (deletion), GSTA1 -69C/T (rs3957357), GSTP1 Ile105Val (rs1695), SOD2 Ala16Val (rs4880) and NRF2 -617C/A (rs6721961) in blood genomic DNA was performed by means of real-time PCR assays. The associations between gene polymorphism and BC risk were computed by logistic regression. The frequency of GSTA1, GSTP1, SOD2 and NRF2 genotypes did not differ in both groups. A significantly higher BC risk was associated with GSTM1 null genotype after adjusting to age, sex and smoking habit (OR 1.85, 95 % CI 1.30-2.62; P = 0.001). GSTT1 null (OR 0.50, 95 % CI 0.31-0.81; P = 0.005) and GSTP1 Val105Val (OR 0.52, 95 % CI 0.27-0.98; P = 0.04) genotypes were associated with reduced BC risk separately or in combination (OR 0.24, 95 % CI 0.11-0.51; P < 0.0001) (P heterogeneity = 0.01). Combined GSTT1 null and SOD2 with at least one 16Val allele among never smokers encompass reduced BC risk (OR 0.14, 95 % CI 0.03-0.63; P = 0.01) (P heterogeneity = 0.04). This study supports hypothesis that GSTM1 null genotype may be a moderate BC risk factor. The gene-gene and gene-environment interactions associated with combined GSTP1/GSTT1 and combined GSTT1/SOD2 genetic polymorphisms along with cigarette smoking habit may play a significant role in BC risk modulation.

MATERIALS
Product Number
Brand
Product Description

Supelco
L-Isoleucine, certified reference material, TraceCERT®
Supelco
L-Isoleucine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Isoleucine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
L-Isoleucine, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
Glutathione S-Transferase from equine liver, lyophilized powder, ≥25 units/mg protein
Sigma-Aldrich
L-Alanine-12C3, 99.9 atom % 12C
Sigma-Aldrich
L-Isoleucine, 99%, FCC, FG
SAFC
L-Isoleucine
Sigma-Aldrich
L-Isoleucine, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
L-Isoleucine, Vetec, reagent grade, ≥98%
Supelco
L-Alanine, certified reference material, TraceCERT®
Supelco
L-Alanine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-Valine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Valine, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
L-Valine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
L-Alanine, ≥98% (TLC)
Sigma-Aldrich
L-Alanine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Supelco
L-Valine, certified reference material, TraceCERT®
Sigma-Aldrich
L-Alanine, ≥99.0% (NT)
Sigma-Aldrich
L-Alanine, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
L-Alanine, ≥99%
Sigma-Aldrich
L-Valine, BioUltra, ≥99.5% (NT)
SAFC
L-Valine
Alanine, European Pharmacopoeia (EP) Reference Standard
Valine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L-Valine, Vetec, reagent grade, ≥98%
Isoleucine, European Pharmacopoeia (EP) Reference Standard